Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Hosokawa, K. Ishii, Y. Kimura, T. Hyodo, M. Hosono, Kenta Sakaguchi, K. Usami, K. Shimamoto, Y. Yamazoe, T. Murakami (2015)
Performance of 11C-Pittsburgh Compound B PET Binding Potential Images in the Detection of Amyloid Deposits on Equivocal Static ImagesThe Journal of Nuclear Medicine, 56
A. Nayate, J. Dubroff, J. Schmitt, I. Nasrallah, R. Kishore, D. Mankoff, D. Pryma (2015)
Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan InterpretationAmerican Journal of Neuroradiology, 36
C. Jack, D. Bennett, K. Blennow, M. Carrillo, B. Dunn, S. Haeberlein, D. Holtzman, W. Jagust, F. Jessen, J. Karlawish, E. Liu, J. Molinuevo, T. Montine, C. Phelps, K. Rankin, C. Rowe, P. Scheltens, E. Siemers, H. Snyder, R. Sperling (2018)
NIA-AA Research Framework: Toward a biological definition of Alzheimer’s diseaseAlzheimer's & dementia : the journal of the Alzheimer's Association, 14
G. Mckhann, D. Drachman, M. Folstein, R. Katzman, D. Price, E. Stadlan (1984)
Clinical diagnosis of Alzheimer's diseaseNeurology, 34
M. Folstein, M. Folstein, S. Folstein, S. Folstein, P. McHugh, P. McHugh (1975)
“Mini-mental state”: A practical method for grading the cognitive state of patients for the clinicianJournal of Psychiatric Research, 12
Keith Johnson, R. Sperling, Christopher Gidicsin, J. Carmasin, Jacqueline Maye, R. Coleman, E. Reiman, M. Sabbagh, C. Sadowsky, A. Fleisher, P. Doraiswamy, A. Carpenter, C. Clark, A. Joshi, M. Lu, M. Grundman, M. Mintun, M. Pontecorvo, D. Skovronsky (2013)
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal agingAlzheimer's & Dementia, 9
S. Landau, D. Harvey, Cindee Madison, R. Koeppe, E. Reiman, N. Foster, M. Weiner, W. Jagust (2011)
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCINeurobiology of Aging, 32
Y. Chen, I. Nasrallah (2017)
Brain amyloid PET interpretation approaches: from visual assessment in the clinic to quantitative pharmacokinetic modelingClinical and Translational Imaging, 5
P. Payoux, J. Delrieu, A. Gallini, A. Gallini, D. Adel, A. Salabert, A. Hitzel, C. Cantet, C. Cantet, M. Tafani, M. Tafani, D. Verbizier, J. Darcourt, P. Fernandez, Jacques Monteil, I. Carrié, T. Voisin, T. Voisin, S. Gillette‐Guyonnet, S. Gillette‐Guyonnet, M. Pontecorvo, B. Vellas, B. Vellas, S. Andrieu (2015)
Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findingsEuropean Journal of Nuclear Medicine and Molecular Imaging, 42
J. Blautzik, M. Brendel, J. Sauerbeck, Sebastian Kotz, Franziska Scheiwein, P. Bartenstein, J. Seibyl, A. Rominger, For Initiative (2017)
Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burdenEuropean Journal of Nuclear Medicine and Molecular Imaging, 44
L. Filippi, A. Chiaravalloti, O. Bagni, O. Schillaci (2018)
18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease.American journal of nuclear medicine and molecular imaging, 8 4
(2021)
Drugs@FDA: FDA-Approved Drugs
Highlights of prescribing information
K. Pothier, L. Saint‐Aubert, C. Hooper, J. Delrieu, P. Payoux, P. Barreto, B. Vellas, M. group (2019)
Cognitive changes of older adults with an equivocal amyloid loadJournal of Neurology, 266
H. Son, Jungsu Oh, Minyoung Oh, Soo‐Jong Kim, Jae-Hong Lee, J. Roh, Jae Kim (2019)
The clinical feasibility of deep learning-based classification of amyloid PET images in visually equivocal casesEuropean Journal of Nuclear Medicine and Molecular Imaging, 47
N. Ranginwala, L. Hynan, M. Weiner, C. White (2008)
Clinical criteria for the diagnosis of Alzheimer disease: still good after all these years.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 16 5
S. Landau, Allison Fero, S. Baker, R. Koeppe, M. Mintun, Kewei Chen, E. Reiman, W. Jagust (2015)
Measurement of Longitudinal β-Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value RatiosThe Journal of Nuclear Medicine, 56
Minyoung Oh, M. Seo, Sun-Young Oh, Heeyoung Kim, B. Choi, Jungsu Oh, Jae Kim (2018)
Clinical significance of visually equivocal amyloid PET findings from the Alzheimer’s Disease Neuroimaging Initiative cohortNeuroReport, 29
S. O'Bryant, S. Waring, C. Cullum, J. Hall, L. Lacritz, P. Massman, P. Massman, P. Lupo, J. Reisch, R. Doody (2008)
Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study.Archives of neurology, 65 8
D. Selkoe (2011)
Alzheimer's disease.Cold Spring Harbor perspectives in biology, 3 7
C. Hosokawa, K. Ishii, T. Hyodo, Kenta Sakaguchi, K. Usami, K. Shimamoto, Y. Yamazoe, M. Hosono, K. Hanada, M. Ueda, K. Saigo, T. Murakami (2015)
Investigation of 11C-PiB equivocal PET findingsAnnals of Nuclear Medicine, 29
S. Landau, S. Landau, B. Thomas, L. Thurfjell, Mark Schmidt, R. Margolin, M. Mintun, M. Pontecorvo, S. Baker, W. Jagust, W. Jagust (2014)
Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracersEuropean Journal of Nuclear Medicine and Molecular Imaging, 41
W. Rosen, R. Mohs, K. Davis (1984)
A new rating scale for Alzheimer's disease.The American journal of psychiatry, 141 11
Rabia Sarroukh, Emilie Cerf, Sylvie Derclaye, Yves Dufrêne, E. Goormaghtigh, J. Ruysschaert, V. Raussens (2011)
Transformation of amyloid β(1–40) oligomers into fibrils is characterized by a major change in secondary structureCellular and Molecular Life Sciences, 68
L. Shaw, H. Vanderstichele, M. Knapik-Czajka, C. Clark, P. Aisen, R. Petersen, K. Blennow, H. Soares, A. Simon, P. Lewczuk, R. Dean, E. Siemers, W. Potter, V. Lee, J. Trojanowski (2009)
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 65
T. Yamane, K. Ishii, M. Sakata, Y. Ikari, T. Nishio, K. Ishii, Takashi Kato, Kengo Ito, M. Senda (2017)
Inter-rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI) multicenter studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 44
(2021)
stopping AD before symptoms begin? Sci Transl Med
R. Sperling, D. Rentz, Keith Johnson, J. Karlawish, M. Donohue, D. Salmon, P. Aisen (2014)
The A4 Study: Stopping AD Before Symptoms Begin?Science Translational Medicine, 6
R. Petersen, P. Aisen, L. Beckett, M. Donohue, A. Gamst, D. Harvey, C. Jack, W. Jagust, L. Shaw, A. Toga, J. Trojanowski, M. Weiner (2010)
Alzheimer's Disease Neuroimaging Initiative (ADNI)Neurology, 74
S. Landau, M. Mintun, A. Joshi, R. Koeppe, R. Petersen, P. Aisen, M. Weiner, W. Jagust (2012)
Amyloid deposition, hypometabolism, and longitudinal cognitive declineAnnals of Neurology, 72
(1964)
L’examen clinique en psychologie [The clinical examination of psychology
G. Mckhann, D. Drachman, M. Folstein, R. Katzman, D. Price, E. Stadlan (2011)
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's DiseaseNeurology, 77
(2012)
Amyvid (Florbetapir F 18 Injection). Highlights of prescribing information. In: Drugs@FDA: FDAApproved Drugs
C. Jack, D. Knopman, W. Jagust, R. Petersen, M. Weiner, P. Aisen, L. Shaw, P. Vemuri, H. Wiste, S. Weigand, T. Lesnick, V. Pankratz, M. Donohue, J. Trojanowski (2013)
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkersThe Lancet Neurology, 12
R. Bateman, C. Xiong, T. Benzinger, A. Fagan, A. Goate, Nick Fox, D. Marcus, N. Cairns, Xianyun Xie, Tyler Blazey, D. Holtzman, A. Santacruz, V. Buckles, A. Oliver, K. Moulder, P. Aisen, B. Ghetti, W. Klunk, E. McDade, R. Martins, C. Masters, R. Mayeux, J. Ringman, M. Rossor, P. Schofield, R. Sperling, S. Salloway, J. Morris (2012)
Clinical and biomarker changes in dominantly inherited Alzheimer's disease.The New England journal of medicine, 367 9
S. Salloway, R. Sperling, Nick Fox, K. Blennow, W. Klunk, M. Raskind, M. Sabbagh, L. Honig, A. Porsteinsson, S. Ferris, M. Reichert, N. Ketter, B. Nejadnik, V. Guenzler, Maja Miloslavsky, Daniel Wang, Yuan Lu, Julia Lull, I. Tudor, E. Liu, M. Grundman, E. Yuen, R. Black, H. Brashear (2014)
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.The New England journal of medicine, 370 4
J. Burns, E. Vidoni, R. Graves, J. Mahnken, Jacqueline Hill, A. Robinson, Nick Harn, Wendell Yap, M. Perry (2015)
Augmenting amyloid PET interpretations with quantitative information improves consistency of cerebral amyloid detectionAlzheimer's & Dementia, 11
V. Cavallucci, M. D’Amelio, F. Cecconi (2012)
Aβ Toxicity in Alzheimer's DiseaseMolecular Neurobiology, 45
K. Blennow, M. Leon, H. Zetterberg (2006)
Alzheimer's diseaseThe Lancet, 368
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
Yi-peng Wang, E. Mandelkow (2015)
Tau in physiology and pathologyNature Reviews Neuroscience, 17
BackgroundTo date, the clinical significance of visually equivocal amyloid positron emission tomography (PET) has not been well established.ObjectiveWe studied the clinical significance of equivocal amyloid PET images from the Alzheimer’s Disease Neuroimaging Initiative (ADNI).MethodsSubjects with F-18 florbetapir PET scans at baseline who were followed up for 4 years were selected. Clinical characteristics, imaging biomarkers, cognitive function, and rate of conversion to AD were compared in subjects with visually equivocal findings.ResultsOf 249 subjects who completed the follow-up, 153 (61.4%), 20 (8.0%), and 129 (30.5%) were F-18 florbetapir-negative, -equivocal, and -positive, respectively. The mean standardized uptake value ratios (SUVR) of F-18 florbetapir PET were 0.75 ± 0.04, 0.85 ± 0.10, and 1.00 ± 0.09 for each group (p <0.001 between groups), and 15.0%, 70.0%, and 98.7% of patients were quantitatively above the positive threshold. The change in the SUVR of F-18 florbetapir PET was higher in the equivocal (6.09 ± 3.61%, p <0.001) and positive (3.13 ± 4.38%, p <0.001) groups than the negative group (0.88 ± 4.28%). Among the subjects with normal or subjective memory impairment and mild cognitive impairment, 5.3% with negative amyloid PET and 37.5% with positive amyloid PET converted to AD over the 4-year period. None of the equivocal amyloid PET subjects converted to AD during this period.ConclusionApproximately 8% of subjects from the ADNI cohort showed visually equivocal amyloid PET scans with intermediate load and rapid accumulation of amyloid, but did not convert to AD during the 4-year follow-up.
Nuclear Medicine and Molecular Imaging – Springer Journals
Published: Mar 4, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.